The Annals of pharmacotherapy · 2000
Management of complications of bacillus Calmette-Guérin immunotherapy in the treatment of bladder cancer.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang T C
Аннотация
OBJECTIVE: To evaluate the management strategies available for the complications associated with bacillus Calmette-Guerin (BCG) immunotherapy in the treatment of bladder cancer.
DATA SOURCES: Clinical literature accessed through MEDLINE (January 1983-January 1999). Key search terms included bacillus Calmette-Guérin, BCG, and bladder cancer.
DATA SYNTHESIS: BCG vaccine is a live-attenuated strain of Mycobacterium bovis; therefore, the risk for complications exists. An evaluation of treatment regimens was conducted, and the management strategies are presented.
CONCLUSIONS: The complications associated with BCG immunotherapy range from local reactions to potentially fatal systemic reactions requiring long-term therapy. Therefore, healthcare practitioners need to be aware of the current treatment regimens available.
DATA SOURCES: Clinical literature accessed through MEDLINE (January 1983-January 1999). Key search terms included bacillus Calmette-Guérin, BCG, and bladder cancer.
DATA SYNTHESIS: BCG vaccine is a live-attenuated strain of Mycobacterium bovis; therefore, the risk for complications exists. An evaluation of treatment regimens was conducted, and the management strategies are presented.
CONCLUSIONS: The complications associated with BCG immunotherapy range from local reactions to potentially fatal systemic reactions requiring long-term therapy. Therefore, healthcare practitioners need to be aware of the current treatment regimens available.